{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:49:00Z","timestamp":1768546140151,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jacig.2025.100609","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:32:04Z","timestamp":1763649124000},"page":"100609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory and fibrotic biomarkers in patients with atopic dermatitis treated with cendakimab"],"prefix":"10.1016","volume":"5","author":[{"given":"Jie","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coryandar","family":"Gilvary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan S.","family":"Dellon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Charriez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia H.M.C.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misti J.","family":"Linaberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2025.100609_bib1","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/ijms21082867","article-title":"Skin barrier abnormalities and immune dysfunction in atopic dermatitis","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacig.2025.100609_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100131","article-title":"Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis","volume":"2","author":"Beck","year":"2022","journal-title":"JID Innov"},{"key":"10.1016\/j.jacig.2025.100609_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/jidsymp.2011.1","article-title":"The role of chronic inflammation in cutaneous fibrosis: fibroblast growth factor receptor deficiency in keratinocytes as an example","volume":"15","author":"Meyer","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jacig.2025.100609_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2025.100609_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.alit.2020.01.005","article-title":"Implications of IL-13R\u03b12 in atopic skin inflammation","volume":"69","author":"Furue","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jacig.2025.100609_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fmed.2017.00139","article-title":"Interleukin-13 in asthma and other eosinophilic disorders","volume":"4","author":"Doran","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jacig.2025.100609_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1165098","article-title":"The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis","volume":"10","author":"Napolitano","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.jacig.2025.100609_bib8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.4049\/jimmunol.174.3.1723","article-title":"CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells","volume":"174","author":"Gunther","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jacig.2025.100609_bib9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/imcb.12644","article-title":"CCL17\/TARC in autoimmunity and inflammation\u2014not just a T-cell chemokine","volume":"101","author":"Lupancu","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jacig.2025.100609_bib10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/eji.200737685","article-title":"CCL27-transgenic mice show enhanced contact hypersensitivity to Th2, but not Th1 stimuli","volume":"38","author":"Kagami","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jacig.2025.100609_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nm0202-157","article-title":"CCL27-CCR10 interactions regulate T cell\u2013mediated skin inflammation","volume":"8","author":"Bernhard","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jacig.2025.100609_bib12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mai.2003.114","article-title":"Increased serum cutaneous T cell\u2013attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris","volume":"111","author":"Kakinuma","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2025.100609_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaci.2006.03.047","article-title":"Cytokines and chemokines orchestrate atopic skin inflammation","volume":"118","author":"Homey","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2025.100609_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2249.2003.02273.x","article-title":"Significant elevation of serum levels of eotaxin-3\/CCL26, but not of eotaxin-2\/CCL24, in patients with atopic dermatitis: serum eotaxin-3\/CCL26 levels reflect the disease activity of atopic dermatitis","volume":"134","author":"Kagami","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jacig.2025.100609_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrd3838","article-title":"Targeting eosinophils in allergy, inflammation and beyond","volume":"12","author":"Fulkerson","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacig.2025.100609_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1006\/cyto.2002.1021","article-title":"Regulation of human eotaxin-3\/ccl26 expression: modulation by cytokines and glucocorticoids","volume":"17","author":"Banwell","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.jacig.2025.100609_bib17","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1007\/s00018-017-2648-0","article-title":"Periostin in inflammation and allergy","volume":"74","author":"Izuhara","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jacig.2025.100609_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2332\/allergolint.13-RAI-0685","article-title":"Periostin in skin tissue skin-related diseases","volume":"63","author":"Yamaguchi","year":"2014","journal-title":"Allergol Int"},{"key":"10.1016\/j.jacig.2025.100609_bib19","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/427285","article-title":"Beneficial regulation of matrix metalloproteinases for skin health","volume":"2011","author":"Philips","year":"2011","journal-title":"Enzyme Res"},{"key":"10.1016\/j.jacig.2025.100609_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1172\/JCI10458","article-title":"Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema","volume":"106","author":"Zheng","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacig.2025.100609_bib21","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s12325-017-0525-8","article-title":"RPC4046, a novel anti\u2013interleukin-13 antibody, blocks IL-13 binding to IL-13 \u03b11 and \u03b12 receptors: a randomized, double-blind, placebo-controlled, dose-escalation first-in-human study","volume":"34","author":"Tripp","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacig.2025.100609_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2025.100609_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.0736-8046.2004.21600.x","article-title":"Serum concentration of IL-18 correlates with disease extent in young children with atopic dermatitis","volume":"21","author":"Hon","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jacig.2025.100609_bib24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3389\/fimmu.2018.00763","article-title":"Unique action of interleukin-18 on T cells and other immune cells","volume":"9","author":"Nakanishi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacig.2025.100609_bib25","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamadermatol.2024.2131","article-title":"Cendakimab in patients with moderate to severe atopic dermatitis: a randomized clinical trial","volume":"160","author":"Blauvelt","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.jacig.2025.100609_bib26","article-title":"Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis","volume":"190","author":"Guttman-Yassky","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacig.2025.100609_bib27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2025.100609_bib28","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2025.100609_bib29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/CM9.0000000000002511","article-title":"Eosinophilic gastroenteritis: pathogenesis, diagnosis, and treatment","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jacig.2025.100609_bib30","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/biom14091080","article-title":"From pathogenesis to treatment: targeting type-2 inflammation in eosinophilic esophagitis","volume":"14","author":"Barchi","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jacig.2025.100609_bib31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacig.2025.100609_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cgh.2020.03.036","article-title":"Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis","volume":"19","author":"Dellon","year":"2021","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829325002103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829325002103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:14:00Z","timestamp":1768482840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829325002103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2772829325002103"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2025.100609","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory and fibrotic biomarkers in patients with atopic dermatitis treated with cendakimab","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2025.100609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100609"}}